Works matching IS 21641153 AND DT 2022 AND VI 12 AND IP 2
Results: 13
New Oncology Drugs and New Indications Approved by the FDA.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 103
- Publication type:
- Article
Sacituzumab plus Pembrolizumab Shows Promising Antitumor Activity in Metastatic Urothelial Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 110
- Publication type:
- Article
Neoadjuvant Enfortumab Vedotin Therapy Promising in Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 109
- Publication type:
- Article
Continuous Treatment with Enzalutamide and Docetaxel Reduces the Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 107
- Publication type:
- Article
First-Line Nivolumab Combination Therapy Improves Survival in Patients with Advanced Esophageal Squamous-Cell Carcinoma: CheckMate-648.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 101
- By:
- Publication type:
- Article
Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 100
- By:
- Publication type:
- Article
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-552.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 99
- By:
- Publication type:
- Article
Comparison of Second-Generation Antiandrogens for the Treatment of Prostate Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 92
- By:
- Publication type:
- Article
Arsenic Trioxide–Induced QTc Interval Prolongation and the Potential Benefit of BetaBlockers in Patients with Acute Promyelocytic Leukemia: Case Series.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 87
- By:
- Publication type:
- Article
Impact of Letermovir for Cytomegalovirus Prophylaxis in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 80
- By:
- Publication type:
- Article
Hepatitis B Virus Infection Monitoring in Patients with Lymphoma Receiving Anti-CD20 Monoclonal Antibodies.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 73
- By:
- Publication type:
- Article
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 66
- By:
- Publication type:
- Article
Protecting Patients with Cancer During the COVID-19 Pandemic .
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 2, p. 61
- By:
- Publication type:
- Article